Cas:1217447-61-4 1-Methyl-L-proline hydrate (1:1) manufacturer & supplier

Chemical Name:1-Methyl-L-proline hydrate (1:1)

CAS.NO:1217447-61-4

Synonyms:N-Methyl-D-proline monohydrate;L-Proline, 1-methyl-, hydrate (1:1);D-Proline, 1-methyl-, hydrate (1:1);1-Methyl-D-proline hydrate (1:1);(2R)-1-methylpyrrolidine-2-carboxylic acid,hydrate;1-Methyl-L-proline hydrate (1:1)

Molecular Formula:C₆H₁₃NO₃

Molecular Weight:147.172

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:49.77000

Exact Mass:147.089539

LogP:0.03880

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-Methyl-D-proline monohydrate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Methyl-L-proline hydrate (1:1) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,D-Proline, 1-methyl-, hydrate (1:1) Use and application,(2R)-1-methylpyrrolidine-2-carboxylic acid,hydrate technical grade,usp/ep/jp grade.

Related News: The FDA issued a stark warning to the public urging them to stop using rapid COVID-19 antigen tests developed by Innova Medical Group, the company previously tapped by the U.K. government for hundreds of millions of kits to help regularly screen the country’s population. 1-Methyl-L-proline hydrate (1:1) manufacturer Compared with individuals with cancer only, those with ASCVD and with ASCVD and cancer had a significantly higher presence of three of more of these factors (23 and 30 percent, respectively, versus 13 percent). 1-Methyl-L-proline hydrate (1:1) supplier The FDA issued a stark warning to the public urging them to stop using rapid COVID-19 antigen tests developed by Innova Medical Group, the company previously tapped by the U.K. government for hundreds of millions of kits to help regularly screen the country’s population. 1-Methyl-L-proline hydrate (1:1) vendor The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. 1-Methyl-L-proline hydrate (1:1) factory The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.